Japan Science & Technology Agency

Japan Science & Technology Agency (JST) is Japan’s national research and development agency focused on promoting science, technology, and innovation. Headquartered in Tokyo, JST funds basic and applied research, supports technology transfer, and manages large-scale research programs on behalf of the Japanese government. In parallel with its programmatic activities, JST oversees significant financial assets, which are invested globally to support long-term funding commitments and grant-making capacity. For U.S. regulatory purposes, JST appears as an institutional investment manager with the U.S. Securities and Exchange Commission under CIK 0001948391. Form 13F filings for Japan Science & Technology Agency disclose its discretionary long positions in U.S.-listed equities and certain equity-linked instruments. These holdings form the U.S. public-equity sleeve of a broader, globally diversified multi-asset portfolio that also includes non-U.S. equities, fixed income, and other asset classes that are not visible in 13F data. The 13F reports typically show diversified exposure to U.S. large- and mid-cap issuers, American Depositary Receipts of non-U.S. companies, and U.S.-listed ETFs used as broad-market building blocks. Sector representation spans information technology, health care, industrials, financials, consumer sectors, and communication services, consistent with benchmark-aware implementation. Within a 13F analytics environment, this disclosure can be organized into a time series of quarter-end portfolios, enabling detailed analysis of JST’s 13F Portfolio Composition and, when normalized to a user-defined starting notional, the construction of an indicative Historical Track Record for the observable U.S. equity sleeve.

JST’s investment strategy is shaped by its mandate as a government R&D agency with long-dated funding obligations. At the total-portfolio level, the focus is on preserving and growing capital in real terms, generating a stable stream of investment income, and maintaining balance-sheet resilience across economic and market cycles. Strategic asset allocation combines high-quality fixed income, global equities, and diversifying assets, often implemented through external managers and pooled vehicles. Within this framework, the U.S. equity allocation captured by Form 13F is long-only and benchmark-aware. Core characteristics of the sleeve, as inferred from filings, include: - Broad exposure to developed-market large- and mid-cap U.S. equities, often via index-tracking funds and diversified mandates rather than concentrated single-stock bets. - Sector diversification closely aligned with major U.S. equity benchmarks, with effective sector tilts driven more by underlying manager choices, quality screens, and valuation discipline than by aggressive top-down sector calls. - A style footprint that is blended, with exposure to both growth and value segments and a tendency toward higher-quality, established franchises compatible with a public-institution risk profile. Turnover in the 13F-visible book appears low to moderate. Core positions in major index constituents and broad ETFs are typically held over extended periods, with adjustments driven by benchmark reconstitutions, manager changes, and periodic rebalancing rather than frequent trading. From the vantage point of a Portfolio Simulator or Backtesting Service, the sequence of quarter-end holdings can be stitched into a rules-based replication of the U.S. sleeve, supporting analysis of its compounding behavior across different market regimes while recognizing that non-U.S. and non-equity components remain off the 13F tape.

Viewed through its SEC filings, Japan Science & Technology Agency is best understood as a Tokyo-based government R&D institution that also functions as a long-horizon institutional investor. Its U.S. equity holdings form a diversified, benchmark-aware sleeve within a global, multi-asset portfolio designed to support future research funding. The 13F record reveals broad sector coverage, reliance on large- and mid-cap issuers and ETFs, and low to moderate turnover—all consistent with a policy-driven, rather than trading-oriented, approach. For allocators and researchers, structuring the agency’s 13F History under CIK 0001948391 into a coherent dataset allows close examination of how its 13F Portfolio Composition has evolved across sectors, capitalization bands, and instruments through different market environments. A normalized reconstruction of the disclosed holdings supports an indicative Historical Track Record, from which one can infer the U.S. sleeve’s capital trajectory relative to major U.S. equity benchmarks and evaluate notional risk-adjusted outcomes via an inferred Sharpe Ratio, observed Max Drawdown Depth, and an estimated Volatility Profile. These diagnostics, generated via Portfolio Simulator tools and Performance Backtests Online, provide a disciplined but partial view of JST’s U.S. equity behavior. Because Form 13F omits non-U.S. assets, fixed income, and other risk-management tools that are central to JST’s overall investment program, all such analytics should be interpreted strictly as a lens on the gross long U.S.-listed equity component. Within that constraint, the key diagnostic question for allocators is how this diversified, benchmark-aware U.S. equity sleeve is likely to respond if equity market leadership and interest-rate conditions shift sharply—between growth and value, cyclical and defensive sectors, or low- and high-rate regimes—over a full research-funding horizon, and whether the historical 13F pattern suggests stable structural tilts or a more adaptive posture as those regimes evolve.

The risk profile implied by Japan Science & Technology Agency’s 13F disclosures is that of a diversified, long-only, benchmark-adjacent U.S. equity sleeve embedded in a larger, liability-aware institutional portfolio. Aggregated into a single notional portfolio, the disclosed holdings are primarily exposed to broad U.S. equity-market beta and sector-factor risks, with idiosyncratic single-name risk moderated by issuer diversification and use of index vehicles. Typical characteristics of a reconstructed sleeve include: - Full coverage of major GICS sectors—information technology, financials, health care, industrials, consumer discretionary and staples, communication services, energy, materials, real estate, and utilities—with relative weights shaped by benchmark composition and manager implementation. - A style bias that leans toward quality and core benchmark names, which can offer some resilience when markets reward balance-sheet strength and earnings stability, but can lag in sharp rallies led by highly speculative or narrow thematic segments. - Low to moderate turnover, resulting in a risk profile that evolves gradually as asset-allocation decisions, index changes, and manager activity filter through the holdings. Because 13F only reports long positions in U.S.-listed equities and certain equity-linked instruments, it does not reveal JST’s substantial fixed-income exposures, non-U.S. securities, currency management, or any derivative overlays that are important to total-fund risk. Within a 13F-driven analytics framework, however, the quarter-end holdings can still be chained into a normalized time series to estimate an indicative Volatility Profile and to approximate portfolio-level Max Drawdown Depth for the reconstructed U.S. equity sleeve. From the same historical replication, a notional Sharpe Ratio can be derived, summarizing risk-adjusted outcomes for the 13F-visible component in isolation.